Sipuleucel-T
DB06688
Approved Indication
Sipuleucel-T is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
1
Targets
0
Resistance Mutations
4
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Sipuleucel-T is designed to induce an immune response targeted against PAP, an antigen expressed in most prostate cancers. During ex vivo culture with PAP-GM-CSF, APCs take up and process the recombinant target antigen into small peptides that are then displayed on the APC surface. The precise mechanism remains unknown, however.
Details
DrugBank ID
DB06688 ↗
Approval Date
2010-04-29
Molecular Weight
— g/mol
Drug Class
Other
ATC Codes
L03AX17
Synonyms
Sipuleucel-T
ChEMBL
CHEMBL1237024 ↗
Drug References (DrugBank)